{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:56:20Z","timestamp":1790592980809,"version":"4.1.0"},"reference-count":31,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Anthracycline-containing intensive chemotherapy remains a standard frontline approach for medically fit patients with acute myeloid leukemia (AML). We retrospectively evaluated an exploratory anthracycline-sparing regimen combining fludarabine, cytarabine, and venetoclax (FLA-VEN), with midostaurin added in FLT3-mutated cases, in selected patients with intermediate- or adverse-risk AML. Methods: This retrospective single-center study included 24 consecutive adults with newly diagnosed intermediate- or adverse-risk AML treated between March 2024 and March 2026. Patients with favorable-risk AML were excluded. The primary endpoints were complete remission (CR) and safety. Secondary endpoints included hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rate, relapse incidence, transplant-related mortality (TRM), and overall survival (OS). Results: The median age was 49 years (range, 22\u201364), and 16.7% of patients were aged \u226560 years. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations were present in 8 patients (33.3%). Following one induction cycle, 21 of 24 patients (87.5%) achieved CR. Among FLT3-ITD-mutated patients, 7 of 8 (87.5%) achieved CR, and FLT3-ITD became undetectable by the available polymerase chain reaction (PCR) fragment assay in all seven responders before transplantation. The 60-day mortality rate was 0\/24 (0%). Median neutrophil and platelet recovery times were 17 and 21 days, respectively. Twenty-one patients (87.5%) underwent allo-HSCT in first remission. With a database cutoff of 30 August 2026, Kaplan\u2013Meier estimated OS was 83.3% (95% CI, 61.5\u201393.4%) at 12 months. The longer-term 24-month OS estimate was 54.4% (95% CI, 25.5\u201376.3%); however, this estimate was imprecise because only five patients remained at risk at 24 months. Median OS was not reached. Conclusions: In this small exploratory cohort, anthracycline-free and G-CSF-free FLA-VEN, with or without midostaurin, was associated with high remission rates, no early mortality, and frequent bridging to allo-HSCT. These findings support prospective controlled evaluation of this anthracycline-sparing strategy.<\/jats:p>","DOI":"10.3390\/cancers18193132","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:00:34Z","timestamp":1790589634000},"page":"3132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Sinem","family":"Namdaroglu","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Kakc\u0131","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrak","family":"\u015eenol","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"\u015eeker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Can","family":"U\u011fur","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences T\u00fcrkiye, \u0130zmir Tepecik Training and Research Hospital, 35020 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nani\u015fe Gizem","family":"Fener","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences T\u00fcrkiye, \u0130zmir Tepecik Training and Research Hospital, 35020 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-9245","authenticated-orcid":false,"given":"Semih","family":"Ba\u015fc\u0131","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmetullah","family":"Batgi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute Myeloid Leukemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Tallman","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/bloodadvances.2021005717","article-title":"ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol","volume":"6","author":"Buccisano","year":"2022","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2021-147200","article-title":"Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia","volume":"138","author":"Venditti","year":"2021","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.15106","article-title":"Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information","volume":"184","author":"Minetto","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukemia: A post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.V124.21.961.961","article-title":"The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease","volume":"124","author":"Saini","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","article-title":"Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial","volume":"107","author":"Milligan","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Mali","year":"2020","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.26892","article-title":"Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"ref_25","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","first-page":"CD002042","article-title":"Transfusion thresholds for guiding red blood cell transfusion","volume":"12","author":"Carson","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mezzanotte, V., Paterno, G., Cerroni, I., De Marchi, L., Taka, K., Buzzatti, E., Mallegni, F., Meddi, E., Moretti, F., and Buccisano, F. (2025). Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041254"},{"key":"ref_29","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, and National Cancer Institute (2026, September 07). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:03:32Z","timestamp":1790589812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":31,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193132"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193132","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]}}}